Plaque Psoriasis

Exact triggers in acute urticaria and chronic urticaria are largely unknown, with the success of identifying causes of AU varying between 21-68%.

Previous research has suggested that psoriasis could affect both fecundity and fertility, leading to spontaneous abortion and ectopic pregnancy.

The current registered dosing of the therapy is 30 mg twice daily, but the analyzed dosage of 20 mg has not yet been approved.

Similarly, patients affected by alopecia areata had higher odds of developing psoriasis.

New 5-year data shows psoriasis improvement was similar among patients with and without metabolic syndrome, regardless of which dose they received.

Dr. McKinley-Grant details the new health movement that aims to stop the cycle of suffering for people of color living with psoriatic disease.

However, comorbidity risk was believed to be substantially different between the two diseases.

Elapsed time following diagnosis, naïve biologic therapy status and previous use of only 1 biologic were associated with higher persistence rates.

New 108 week data found that treatment with the biologic resulted in significant skin clearance in pediatric patients with psoriasis.

In recent years, researchers and advocates have vocalized increasing psychological support for patients with psoriasis.

A consensus was reached on nearly all proposals in the eDelphi study, which members said could be used to establish a clear dosing regimen for methotrexate.

An assessment of long-term VOYAGER 1 and 2 trial data show the IL-23 biologic provides significant benefit toward skin clearance, regardless of baseline characteristics.

Clinical responses including PASI 100 and absolute PASI, and PASI ≤2 were maintained through week 96 with the biologic in patients with psoriasis, with no new safety signals identified.

The new oral medicine helped some patients with mild to moderate psoriasis achieve and sustain PASI-50 after the initial study period.

New phase 4 data suggests that apremilast could be used to improve cardiometabolic function in patients with psoriatic disease.

New AAD 2022 pooled analysis show the PDE-4 inhibitor topical therapy provides tolerable and effective improvement at 8 weeks.

Dr. Daphne Chan spoke of representation in psoriasis trials, how psoriasis affects different skin types, and how the VISIBLE study can influence dermatology research at large.

IL-17 inhibitors were also associated with higher persistence than IL-12 and IL-23 inhibitors for psoriatic arthritis, though no difference was observed for psoriasis.

Dr Jerry Bagel looks to the future of moderate-to-severe plaque psoriasis management.

Investigators note that the histopathologic diagnosis of inflammatory skin disorders can prove challenging, with psoriasis being particularly heterogeneous and dynamic.

Side effects of the vaccines occurred at a lower incidence in the current study.

Patients with psoriasis slept 1 hour less than control subjects, and associations with anxiety and depression were observed.

Jerry Bagel, MD, MS, explains clinical trial data on the investigational anti-IL17A/F monoclonal antibody bimekizumab.

An overview of the novel selective tyrosine kinase 2 (TYK2) inhibitor deucravacitinib for the management of plaque psoriasis.

Dr Jerry Bagel describes the unmet needs of plaque psoriasis management.